Aviceda Therapeutics, a private clinical-stage biotech company, announced that the US Food and Drug Administration (FDA) has cleared the IND for AVD-104, enabling the company to proceed with initiating phase 2 clinical trials of its lead intravitreal ocular asset for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The phase 2 SIGLEC trial is expected to begin in Q2 2023.
